Publications by authors named "Mariapaola Farinelli"
Vaccines (Basel)
May 2024
Article Synopsis
- RSV bronchiolitis is a major health concern for newborns and infants, leading to hospitalization and complications in their first year of life.
- Nirsevimab, a newly developed monoclonal antibody, has shown promise for preventing RSV, and Valle d'Aosta in Italy has implemented a universal prophylaxis program for newborns during the 2023-2024 epidemic season.
- The study found that hospitalization rates for RSV bronchiolitis dropped significantly to 3.2% in 2023-2024, with no hospitalized cases in infants who received nirsevimab, indicating its effectiveness and safety.
